Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia

Recruiting

Trial ID: NCT04770922

Age - N/A-21 Years Gender - All Accepting Healthy Volunteers - No

Purpose

This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.

Official Title

Pharmacogenomic Analysis of 6-mercaptopurine in Pediatric Acute Lymphoblastic Leukemia

Stanford Investigator(s)

Kathleen M. Sakamoto

Stephanie Melissa Smith

Instructor, Pediatrics - Hematology & Oncology

Eligibility


Inclusion Criteria:

   - Pediatric acute lymphoblastic leukemia (ALL) subjects

   - Received 6-mercaptopurine

   - Available biobank (bone marrow or blood) sample(s) from which deoxyribonucleic acid
   (DNA) can be extracted

   - White blood cell (WBC) levels

Exclusion Criteria:

   - Pediatric ALL subjects who did NOT receive 6-mercaptopurine

   - No biobank sample

   - No WBC level

View More
View Less

Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

©2022 Stanford Medicine